Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.16 USD
+0.10 (0.29%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $34.11 -0.05 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
INBX 34.16 +0.10(0.29%)
Will INBX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for INBX
As more rare disease therapies launch, their prices are rising
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX) and Inhibrx (INBX)
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
Inhibrx just downgraded at Jefferies, here's why